Venclyxto 100 Tablets — Venetoclax 100 mg (112 Tabs) AbbVie
Venclyxto 100 mg (Venetoclax) is a breakthrough, original targeted cancer therapy. It is the first-in-class selective inhibitor of the BCL-2 protein. This protein builds up in certain cancer cells and prevents them from dying naturally. By blocking BCL-2, Venclyxto restores the apoptosis (programmed cell death) process, causing the rapid destruction of leukemia cells.
Manufacturer: AbbVie. 🇹🇷 Note: This specific product holds official Turkish registration and is packaged for the domestic market of Turkey, ensuring the highest standards of original medication quality.
Key Features:
- ✅ Unique Mechanism: Directly triggers the self-destruction sequence (apoptosis) within malignant cells.
- ✅ Deep Remission: Highly effective even in patients with challenging genetic profiles (e.g., 17p deletion or TP53 mutation).
- ✅ Original Brand: Manufactured by AbbVie, the original developer of the venetoclax molecule.
Prescribed by a hematologist-oncologist for the treatment of adult patients with:
- 🔹 Chronic Lymphocytic Leukemia (CLL): Used as monotherapy or in combination with rituximab/obinutuzumab (for both previously untreated and relapsed/refractory patients).
- 🔹 Acute Myeloid Leukemia (AML): In combination with hypomethylating agents for newly diagnosed patients who are ineligible for intensive chemotherapy due to age or comorbidities.
Sales Unit: Multipack carton containing 112 film-coated tablets (4 inner boxes of 28 tablets each). Strength: 100 mg per tablet.
⚠️ APPLICATION INSTRUCTIONS:
- Ramp-Up Schedule: Treatment for CLL must begin with a 5-week dose escalation phase (starting at 20 mg and building up to the target dose of 400 mg) to prevent severe Tumor Lysis Syndrome. Never start directly with 100 mg tablets!
- Administration: Take once daily at approximately the same time. Must be taken with a meal and a glass of water. Swallow tablets whole.
- ✋ Dietary Warning: Do not consume grapefruit, Seville oranges, or starfruit while taking this medication.
- ⛔ Strong CYP3A Inhibitors: Concomitant use during the dose ramp-up phase is strictly contraindicated due to a high risk of fatal Tumor Lysis Syndrome.
- Pregnancy and breastfeeding (highly effective contraception is required).
- Administration of live attenuated vaccines during and after treatment until B-cell recovery.
- Children and adolescents under 18 years of age.
Treatment requires rigorous medical supervision and frequent blood tests. Potential side effects include:
- ⚠️ Tumor Lysis Syndrome (TLS): A life-threatening condition caused by the rapid breakdown of cancer cells (requires high hydration and uric acid reducers during the ramp-up phase).
- 🩸 Blood Counts: Neutropenia (very common, requires monitoring), anemia.
- 🦠 Infections: Increased susceptibility to upper respiratory tract infections and pneumonia.
- 🤢 Gastrointestinal: Diarrhea, nausea, vomiting, constipation.
- 💤 General: Fatigue.
Similar products
What Customers Say
No reviews yet
Your review can be the first!